Avitia's Cancer Diagnostics FAQs

Avitia is a modular and cost-effective molecular diagnostics oncology solutions that improves patient outcomes. We empower labs and clinicians with innovative, end-to-end cancer diagnostics that reduce costs and improve access to personalized treatments.

Avitia’s artificial intelligence (AI) and machine learning (ML) platform seamlessly integrates into any lab — rapidly provides advanced bioinformatics and personalized treatment planning. The company's solution empowers clinical labs and oncologists to perform on-site precision cancer diagnostics, which accelerates patient management.

Avitia’s NGS-based molecular tests are tailored for clinical and research applications. Our targeted tissue and liquid biopsy panels are robust performing — ensuring patient tumor testing results are accurate, actionable, as well as timely. Additionally, Avitia’s streamlined processes and advanced technology are built to integrate with comprehensive tests like CGP and low-pass whole genome. This provides labs and oncologists with diagnostic flexibility, as well as operational efficiency.

Avitia’s technology is currently used by partners in Canada, the Middle East, and Southeast Asia. With over 40,000 life-saving cancer mutation tests already run using this technology, Avitia affirms its role as a trusted partner in transforming global cancer care.

With the solution utilizing widely available materials and a modular technology system, Avitia eliminates the need for proprietary testing kits and supports equipment flexibility — reducing costs without compromising quality. This ensures accessibility to high-quality NGS testing solutions for labs of all sizes — even in underserved regions.

Avitia is transforming global oncology diagnostics by creating modular, scalable, and cost-effective solutions that allow targeted treatments for better patient outcomes. By targeting cancer with precision, Avitia puts time back on the patients’ side and reduces the need for unnecessary procedures and treatments.